Saruc, M. Et Al. 2003. Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Journal of Pharmaceutical Sciences , vol.92, no.7 , 1386-1395.

Saruc, M., Ozden, N., Turkel, N., AYHAN, S., Hock, L. M., Tuzcuoglu, I., ... Yuceyar, H.(2003). Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Journal of Pharmaceutical Sciences , vol.92, no.7, 1386-1395.

Saruc, Murat Et Al. "Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B," Journal of Pharmaceutical Sciences , vol.92, no.7, 1386-1395, 2003

Saruc, Murat Et Al. "Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B." Journal of Pharmaceutical Sciences , vol.92, no.7, pp.1386-1395, 2003

Saruc, M. Et Al. (2003) . "Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B." Journal of Pharmaceutical Sciences , vol.92, no.7, pp.1386-1395.

@article{article, author={Murat Saruc Et Al. }, title={Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B}, journal={Journal of Pharmaceutical Sciences}, year=2003, pages={1386-1395} }